Europe is entering a new era of evidence-driven healthcare, where Real-World Data (RWD) and Real-World Evidence (RWE) are becoming strategic assets for regulatory decision-making, public health preparedness, and health policy development.

At the center of this transformation is DARWIN EU® (Data Analysis and Real-World Interrogation Network), a pan-European initiative established by the European Medicines Agency (EMA) to provide timely, high-quality evidence from real-world healthcare data throughout the lifecycle of medicines. DARWIN EU® 2 represents the next phase of this ambitious vision, with the programme set to develop further over the next five years.

DARWIN EU® 2 will further expand Europe’s existing federated data network. Rather than moving healthcare data into a central repository, data remain within national or institutional environments, while analyses are conducted across the distributed network. Only aggregated and anonymized results are shared, supporting both scalability and compliance with European data protection requirements.

A growing emphasis is also being placed on artificial intelligence capabilities. The DARWIN EU® 2 infrastructure is expected to leverage AI to support data onboarding, improve analytical processes, enhance efficiency and quality, and facilitate the reuse of study outputs for the training and validation of AI algorithms, in line with the EU Life Sciences Strategy and the EU AI Act.

Equally important is the planned integration with the European Health Data Space (EHDS). As increasing numbers of healthcare datasets become available for secondary use through the EHDS framework, DARWIN EU® 2 is expected to significantly expand its network, analytical capacity, and ability to address complex regulatory and public health questions across Europe.

The implications extend far beyond medicines regulation. A strengthened DARWIN EU® ecosystem could support faster responses to pandemics and emerging public health threats, more effective medicines safety monitoring, and better understanding of healthcare system challenges. EMA, ECDC, HTA bodies, National Competent Authorities, and other stakeholders will increasingly be able to draw on robust real-world evidence to support decision-making.

Europe’s strategic direction is clear: the objective is no longer simply to collect healthcare data, but to build a trusted, interoperable, AI-enabled ecosystem capable of transforming data into evidence and evidence into better health policy decision-making.

Within this transformation, DARWIN EU® 2 is emerging as the central pillar of Europe’s evolving digital health and evidence-generation infrastructure.